Search

Displaying results 1181 - 1190 of 1723 in total
  1. Drug

    Pegzilarginase

    go.drugbank.com/drugs/DB14780
    Approved

    FDA in February 2026 for the treatment of hyperargininemia in adult and pediatric patients aged 2 years and older with ARG1-D, to be used in conjunction with dietary protein restriction.

  2. Drug

    Mangafodipir

    go.drugbank.com/drugs/DB06796
    ApprovedInvestigationalWithdrawn

    Teslascan has been removed from the Drug Product List by FDA in 2003, and withdrawn from the European market in 2012.

  3. Drug

    Fluoroestradiol F-18

    go.drugbank.com/drugs/DB15690
    ApprovedInvestigational

    [A203912] Fluoroestradiol F-18 was first granted FDA approval in May 2020, and will be developed by PETNET Solutions, Inc. and Zionexa USA under the brand name Cerianna.

  4. Drug

    Fentanyl

    go.drugbank.com/drugs/DB00813
    ApprovedIllicitInvestigationalVet approved

    [L6751] Fentanyl was FDA approved in 1968.[Label,L6598,L6601,L6604,L6607,L922,L6610,L6613]

  5. Drug

    Trazodone

    go.drugbank.com/drugs/DB00656
    ApprovedInvestigational

    [T646] It was initially granted FDA approval in 1981.[L3484]

  6. Drug

    Estriol

    go.drugbank.com/drugs/DB04573
    ApprovedInvestigationalVet approved

    Though estriol is used as part of the primarily North American phenomenon of bioidentical hormone replacement therapy, it is not approved for use by the FDA or Health Canada.

  7. Drug

    Digoxin

    go.drugbank.com/drugs/DB00390
    ApprovedInvestigational

    [A178234] Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954.

  8. Drug

    Methocarbamol

    go.drugbank.com/drugs/DB00423
    ApprovedInvestigationalVet approved

    [L6295] Methocarbamol was FDA approved on 16 July 1957.[L6265]

  9. Drug

    Anthrax immune globulin human

    go.drugbank.com/drugs/DB09057
    ApprovedInvestigational

    Available as the product Anthrasil (FDA), the result is a solution for slow IV infusion containing polyclonal antibodies that bind the protective antigen (PA) component of Bacillus anthracis lethal and

  10. Drug

    Peramivir

    go.drugbank.com/drugs/DB06614
    ApprovedInvestigational

    The injectable intravenous formulation of peramivir was approved by the FDA in September 2017 for the treatment of acute uncomplicated influenza to pediatric patients 2 years and older who have been symptomatic